Sensorineural Hearing Loss: Causes and Hearing Rehabilitation

Moo Jin Baek

doi:10.7599/hmr.2015.35.2.57

Journal List > Hanyang Med Rev > v.35(2) > 1044252

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Baek: Sensorineural Hearing Loss: Causes and Hearing Rehabilitation

Review Article

Hanyang Medical Reviews 2015; 35(2): 57-65.

Published online: 21 May 2015

DOI: https://doi.org/10.7599/hmr.2015.35.2.57

Sensorineural Hearing Loss: Causes and Hearing Rehabilitation

Moo Jin Baek

Department of Otorhinolaryngology, Inje University, Haeundae Paik Hospital, Busan, Korea.

Correspondence to: Moo Jin Baek. Department of Otorhinolaryngology, Inje University, Haeundae Paik Hospital, 875 Haeun-daero, Haeundae-gu, Busan 612-896, Korea. Tel: +82-51-797-1609, Fax: +82-51-797-2304, mjbaek@inje.ac.kr

Received 26 February 2015 Revised 15 March 2015 Accepted 23 March 2015

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Sensorineural hearing loss is one of the most common chronic clinical disorders that we can easily encounter. The etiology of sensorineural hearing loss is multifactorial: congenital, idiopathic, traumatic, noise-induced, head injury induced, infectious disease, drug induced, degenerative, immune disorder, vestibular schwannoma and Meniere's disease. Many people are living with the discomfort of hearing loss because fundamental treatment is has not yet been found. Also due to the progress of medical science, human life span has been extended. As the result, the number of patients suffering from hearing loss has increased. But the present situation does not measure up to the demand for recovery of hearing loss. Hearing loss has a great influence on the quality of life. To overcome this situation, neural prostheses such as the cochlear implant and auditory brainstem implant are helpful for the rehabilitation of total deaf patients. Recently, due to the advancement of studies related to hair cell regeneration and the field of gene therapy on the inner ear has made big progress during the last few years. The purpose of this study is to describe the latest known causes and rehabilitation of sensorineural hearing loss.

Keywords: Hearing Loss, Sensorineural, Correction of Hearing Impairment

Figures and Tables

Fig. 1

Various anatomical locations of hearing rehabilitation methods from hearing aid (peripheral) to auditory brainstem implant (central). MEI, middle ear implant; Cis, cochlear implant; ABI, auditory brainstem implant.

Table 1

Causes of sensorineural hearing loss

References

1. Yamane H, Nakai Y, Takayama M, Iguchi H, Nakagawa T, Kojima A. Appearance of free radicals in the guinea pig inner ear after noise-induced acoustic trauma. Eur Arch Otorhinolaryngol. 1995; 252:504–508.

2. Kujawa SG1, Liberman MC. Adding insult to injury: cochlear nerve degeneration after "temporary" noise-induced hearing loss. J Neurosci. 2009; 29:14077–14085.

3. Canlon B, Meltser I, Johansson P, Tahera Y. Glucocorticoid receptors modulate auditory sensitivity to acoustic trauma. Hear Res. 2007; 226:61–69.

4. Gao G, Liu Y, Zhou CH, Jiang P, Sun JJ. Solid lipid nanoparticles loaded with edaravone for inner ear protection after noise exposure. Chin Med J (Engl). 2015; 128:203–209.

5. Kopke R, Slade MD, Jackson R, Hammill T, Fausti S, Lonsbury-Martin B, et al. Efficacy and safety of N-acetylcysteine in prevention of noise induced hearing loss: A randomized clinical trial. Hear Res. 2015; 323:40–50.

6. Yamashita D, Sun GW, Cui Y, Mita S, Otsuki N, Kanzaki S, et al. Neuroprotective effects of cutamesine, a ligand of the sigma-1 receptor chaperone, against noise-induced hearing loss. J Neurosci Res. 2015; 93:788–795.

7. Voldrich L. Noise-noise effect upon the spreading of the posttraumatic progressive necrosis in the organ of Corti. Arch Otorhinolaryngol. 1979; 222:169–173.

8. Chi FL, Yang MQ, Zhou YD, Wang B. Therapeutic efficacy of topical application of dexamethasone to the round window niche after acoustic trauma caused by intensive impulse noise in guinea pigs. J Laryngol Otol. 2011; 125:673–685.

9. Cunningham LL, Tucci DL. Restoring synaptic connections in the inner ear after noise damage. N Engl J Med. 2015; 372:181–182.

10. Rybak LP, Ramkumar V. Ototoxicity. Kidney Int. 2007; 72:931–935.

11. Jiang H, Sha SH, Schacht J. NF-kappaB pathway protects cochlear hair cells from aminoglycoside-induced ototoxicity. J Neurosci Res. 2005; 79:644–651.

12. Sha SH, Schacht J. Antioxidants attenuate gentamicin-induced free radical formation in vitro and ototoxicity in vivo: D-methionine is a potential protectant. Hear Res. 2000; 142:34–40.

13. Kim YH, Raphael Y. Cell division and maintenance of epithelial integrity in the deafened auditory epithelium. Cell Cycle. 2007; 6:612–619.

14. Yamasoba T, Lin FR, Someya S, Kashio A, Sakamoto T, Kondo K. Current concepts in age-related hearing loss: epidemiology and mechanistic pathways. Hear Res. 2013; 303:30–38.

15. Pujol R, Rebillard G, Puel JL, Lenoir M, Eybalin M, Recasens M. Glutamate neurotoxicity in the cochlea: a possible consequence of ischaemic or anoxic conditions occurring in ageing. Acta Otolaryngol Suppl. 1990; 476:32–36.

16. Alam SA, Oshima T, Suzuki M, Kawase T, Takasaka T, Ikeda K. The expression of apoptosis-related proteins in the aged cochlea of Mongolian gerbils. Laryngoscope. 2001; 111:528–534.

17. Tadros SF, Frisina ST, Mapes F, Frisina DR, Frisina RD. Higher serum aldosterone correlates with lower hearing thresholds: a possible protective hormone against presbycusis. Hear Res. 2005; 209:10–18.

18. Garringer HJ, Pankratz ND, Nichols WC, Reed T. Hearing impairment susceptibility in elderly men and the DFNA18 locus. Arch Otolaryngol Head Neck Surg. 2006; 132:506–510.

19. McHugh RK, Friedman RA. Genetics of hearing loss: allelism and modifier genes produce a phenotypic continuum. Anat Rec A Discov Mol Cell Evol Biol. 2006; 288:370–381.

20. Unal M, Tamer L, Doğruer ZN, Yildirim H, Vayisoğlu Y, Camdeviren H. N-acetyltransferase 2 gene polymorphism and presbycusis. Laryngoscope. 2005; 115:2238–2241.

21. Rosenhall U, Sixt E, Sundh V, Svanborg A. Correlations between presbyacusis and extrinsic noxious factors. Audiology. 1993; 32:234–243.

22. Seidman MD. Effects of dietary restriction and antioxidants on presbyacusis. Laryngoscope. 2000; 110:727–738.

23. Martin del Camp HN, Measor KR, Razak KA. Parvalbumin immunoreactivity in the auditory cortex of a mouse model of presbycusis. Hear Res. 2012; 294:31–39.

24. Han C, Someya S. Mouse models of age-related mitochondrial neurosensory hearing loss. Mol Cell Neurosci. 2013; 55:95–100.

25. Iwai H, Inaba M. Fetal thymus graft prevents age-related hearing loss and up regulation of the IL-1 receptor type II gene in CD4(+) T cells. J Neuroimmunol. 2012; 250:1–8.

26. Prisman E, Ramsden JD, Blaser S, Papsin B. Traumatic perilymphatic fistula with pneumolabyrinth: diagnosis and management. Laryngoscope. 2011; 121:856–859.

27. Kobayashi T, Sakurada T, Ohyama K, Takasaka M. Inner ear injury caused by air intrusion to the scala vestibuli of the cochlea. Acta Otolaryngol. 1993; 113:725–730.

28. Woo HJ, Song SY, Kim YD, Bai CH. Pneumolabyrinth without temporal bone fracture: different outcomes for hearing recovery. Laryngoscope. 2008; 118:1464–1466.

29. Kadambari S, Williams EJ, Luck S, Griffiths PD, Sharland M. Evidence based management guidelines for the detection and treatment of congenital CMV. Early Hum Dev. 2011; 87:723–728.

30. Sabella C. Measles: not just a childhood rash. Cleve Clin J Med. 2010; 77:207–213.

31. Nalamachu S, Morley-Forster P. Diagnosing and managing postherpetic neuralgia. Drugs Aging. 2012; 29:863–869.

32. Ozen M, Kanra G, Kara A, Ataş A, Seçmeer G, Ceyhan M, et al. Long-term effects of dexamethasone on hearing ability in children with pneumococcal meningitis. Turk J Pediatr. 2008; 50:23–29.

33. Coimbra RS, Loquet G, Leib SL. Limited efficacy of adjuvant therapy with dexamethasone in preventing hearing loss due to experimental pneumococcal meningitis in the infant rat. Pediatr Res. 2007; 62:291–294.

34. Franco-Vidal V, Beurg M, Darrouzet V, Bébéar JP, Skinner LJ, Dulon D. Zinc protection against pneumolysin toxicity on rat cochlear hair cells. Audiol Neurootol. 2008; 13:65–70.

35. Klein M, Koedel U, Kastenbauer S, Pfister HW. Nitrogen and oxygen molecules in meningitis-associated labyrinthitis and hearing impairment. Infection. 2008; 36:2–14.

36. Durisin M, Büchner A, Lesinski-Schiedat A, Bartling S, Warnecke A, Lenarz T. Cochlear implantation in children with bacterial meningitic deafness: the influence of the degree of ossification and obliteration on impedance and charge of the implant. Cochlear Implants Int. 2015; 16:147–158.

37. Kingston M, French P, Goh B, Goold P, Higgins S, Sukthankar A, et al. UK National Guidelines on the Management of Syphilis 2008. Int J STD AIDS. 2008; 19:729–740.

38. Shea PF, Richey PA, Wan JY, Stevens SR. Hearing results and quality of life after streptomycin/dexamethasone perfusion for Meniere's disease. Laryngoscope. 2012; 122:204–211.

39. Pacheu-Grau D, Pérez-Delgado L, Gómez-Díaz C, Fraile-Rodrigo J, Montoya J, Ruiz-Pesini E. Mitochondrial ribosome and Ménière's disease: a pilot study. Eur Arch Otorhinolaryngol. 2012; 269:2003–2008.

40. Fisher LM, Derebery MJ, Friedman RA. Oral steroid treatment for hearing improvement in Ménière's disease and endolymphatic hydrops. Otol Neurotol. 2012; 33:1685–1691.

41. Shea JJ Jr. The role of dexamethasone or streptomycin perfusion in the treatment of Meniere's disease. Otolaryngol Clin North Am. 1997; 30:1051–1059.

42. Boleas-Aguirre MS, Lin FR, Della Santina CC, Minor LB, Carey JP. Longitudinal results with intratympanic dexamethasone in the treatment of Ménière's disease. Otol Neurotol. 2008; 29:33–38.

43. Solares CA, Edling AE, Johnson JM, Baek MJ, Hirose K, Hughes GB, et al. Murine autoimmune hearing loss mediated by CD4+ T cells specific for inner ear peptides. J Clin Invest. 2004; 113:1210–1217.

44. Billings PB, Keithley EM, Harris JP. Evidence linking the 68 kilodalton antigen identified in progressive sensorineural hearing loss patient sera with heat shock protein 70. Ann Otol Rhinol Laryngol. 1995; 104:181–188.

45. Hirose K, Wener MH, Duckert LG. Utility of laboratory testing in autoimmune inner ear disease. Laryngoscope. 1999; 109:1749–1754.

46. Nair TS, Kozma KE, Hoefling NL, Kommareddi PK, Ueda Y, Gong TW, et al. Identification and characterization of choline transporter-like protein 2, an inner ear glycoprotein of 68 and 72 kDa that is the target of antibody-induced hearing loss. J Neurosci. 2004; 24:1772–1779.

47. Passali D, Damiani V, Mora R, Passali FM, Passali GC, Bellussi L. P0 antigen detection in sudden hearing loss and Ménière's disease: a new diagnostic marker? Acta Otolaryngol. 2004; 124:1145–1148.

48. Liu YC, Rubin R, Sataloff RT. Treatment-refractory autoimmune sensorineural hearing loss: response to infliximab. Ear Nose Throat J. 2011; 90:23–28.

49. Cohen S, Roland P, Shoup A, Lowenstein M, Silverstein H, Kavanaugh A, et al. A pilot study of rituximab in immune-mediated inner ear disease. Audiol Neurootol. 2011; 16:214–221.

50. Hamid M, Trune D. Issues, indications, and controversies regarding intratympanic steroid perfusion. Curr Opin Otolaryngol Head Neck Surg. 2008; 16:434–440.

TOOLS

Similar articles